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Abstract
The intestinal microbiota is a large and diverse microbial community that inhabits the intestine, containing about
100 trillion bacteria of 500-1000 distinct species that, collectively, provide benefits to the host. The human gut
microbiota composition is determined by a myriad of factors, among them genetic and environmental, including
diet and medication. The microbiota contributes to nutrient absorption and maturation of the immune system. As
reciprocity, the host immune system plays a central role in shaping the composition and localization of the intestinal
microbiota. Secretory immunoglobulins A (sIgAs), component of the adaptive immune system, are important player in
the protection of epithelium, and are known to have an important impact on the regulation of microbiota composition.
A recent study published in Immunity by Fransen and colleagues aimed to mechanistically decipher the interrelationship
between sIgA and microbiota diversity/composition. This commentary will discuss these important new findings, as well
as how future therapies can ultimately benefit from such discovery.
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Background
The gut host defense system comprises an array of
mechanisms to keep the microbiota in check, main-
taining an orderly beneficial relationship with the
intestinal microbiota [1]. These mechanisms include
the presence of multi-layered mucus structures, secre-
tion of anti-microbial peptides and the secretion of
sIgA. Additionally, the mucosal immune system has
several means to sample and evaluate potential danger
of microbiota-derived antigens, allowing production of
specific antibodies to bacterial antigens that might
compromise the host. Adaptive immunity in general,
and sIgA in particular, is known to play a key role in
microbiota composition. Here, we will discuss recent
findings describing how IgAs population has an
impact on microbiota diversity, and how they may
provide therapeutic insights into diseases associated
with dysbiosis [2].
Immunoglobulin A-mediated modulation of the intestinal
microbiota
A key intestinal strategy to generate immune protection
in a non-inflammatory manner is the production of IgA
[3–5], which is schematically illustrated in Fig. 1. One
of the main role played by IgA is the promotion of
immune exclusion by entrapping dietary antigens and
microorganisms in the mucus, or down-regulating the
expression of pro-inflammatory bacterial epitopes on
commensal bacteria, such as flagellin [6]. IgA population
in the gut is central for the selection and the maintenance
of the intestinal microbiota [7, 8].
The main observation showing the importance of
immunoglobulin in microbiota composition regulation
was made with animals lacking such Ig production.
Microbiota analysis of RAG1-/- mice (which have no
adaptive immune system owing to the lack of V(D)J
recombination-activating protein 1 (RAG1)) revealed
profound alterations in their microbiota composition [9].
Moreover, it was observed that the restoration of normal
IgA levels in AID (activation-induced cytidine deaminase)
deficient mice, which normally lack IgAs, is sufficient to
restore a normal microbiota composition [7, 10, 11].
Another important observation showing that intestinal
IgA help to shape the intestinal microbiota is the recent
* Correspondence: bchassaing@gsu.edu
2Institute for Biomedical Sciences, Center for Inflammation, Immunity, and
Infection, Georgia State University, Atlanta, GA 30303, USA
Full list of author information is available at the end of the article
The Microbiome and Man
© 2016 Dollé et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dollé et al. BMC Medicine  (2016) 14:27 
DOI 10.1186/s12916-016-0573-y
finding that cessation of breast-feeding to either for-
mula or food drives the maturation of the infant gut
microbiome, indicating that the important amount of
IgA secreted in mother’s milk seems to play a central
role in the regulation of microbiota composition [12].
Mounting evidence clearly reveals that bacterial species
colonizing the gut differ in their ability to stimulate the
post-natal maturation of the gut system, with a good
example being segmented filamentous bacteria (SFB)
which are potent stimuli of IgA responses and strong
inducers of Peyer’s patches development [13, 14].
Polyreactive IgA diversity controls microbiota
composition and diversity
Fransen and collaborators recently demonstrated that
the abundance and repertoire diversity of innate IgAs
(also referred to as polyreactive due to their ability to
bind multiple antigens) play a central role in regulating
the diversity of the intestinal microbiota [2, 15]. The
authors observed that C57BL/6 and BALB/c mice differ
drastically in their IgA abundance and repertoire rich-
ness, which associate with profound differences in their
microbiota composition. While BALB/c mice have a high
abundance and diversity of IgAs, C57BL/6 mice harbor a
poor IgA repertoire correlating with a decreased micro-
biota diversity. Even under germfree conditions (germfree
animals are devoid of any microorganisms), C57BL/6 and
BALB/c mice differ in polyreactive IgA, revealing a genetic
component of IgA production. Importantly, those poly-
reactive IgA were found by the authors to determinate the
capacity of the strain of mice to diversify the microbiota.
Delving deeper into the mechanisms of such interrelation-
ship between polyreactive IgA and microbiota diversity,
the authors demonstrated that polyreactive IgAs are
required to trigger IgA response toward members of
the intestinal microbiota, through a coating that favor
bacterial penetration into Peyer’s patches [2]. Those
findings further demonstrate that microbiota diversity
is both genetically and environmentally driven, mech-
anistically supporting earlier observations [16].
However, it is important to note that low IgA diversity
is not the exclusive discrepancy found between these 2
mice strains. Among other differences, C57BL/6 mice
have a normal Th1 response while BALB/c mice are
deficient in Th1 signaling, which could also have an im-
portant impact on the phenotypes described in this study.
Fig. 1 Interplay between IgA and the microbiota in the intestine. Schematic representation of IgA generation in the intestine, and how IgA population
and intestinal microbiota regulate each other. Symbol 1: intestinal antigen sampling, mainly through M-cells process, is the first step in IgA plasma cells
generation and IgA synthesis. IgA population and diversity will depend on antigenic peptides presented to the immune system by antigen-presenting
cell. Symbol 2: after interaction with its receptor, IgA dimers are translocated to the lumen where they will provide mucosal immune protection. In
addition, such secreted IgA can subsequently regulate microbiota composition, diversity, and gene expression. SED: sub-epithelial dome; DC:
dendritic cell
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One important point that still needs to be addressed is
whether the decreased microbiota diversity observed in
C57BL/6 mice, as a result of low IgA diversity, is asso-
ciated with an increased pro-inflammatory potential/
harmfulness. The investigations of whether the altered
microbiota associated with low intestinal IgA predis-
pose mice of subsequent challenges still need to be
conducted.
Immunoglobulin-based therapy for microbiota
composition alteration and restoration?
It is important to note that, in the study by Fransen and
colleagues, co-housing or fecal transplantation had little ef-
fect on both IgA production and microbiota composition,
highlighting the stability of the intestinal microbiota in an
individual, with a central role played by IgA repertoire [2].
The defined repertoire of IgAs controls the colonization
and composition of the microbiota and will lead to the res-
toration of the original microbiota following alteration.
Consequently, such findings suggest that modulation of
IgA repertoire could lead to a more drastic and stable
alteration in the intestinal microbiota compared to, for
example, fecal transplantation. Moreover, it has been
observed that mice bred in different facilities harbor a
distinct microbiota that further determines the levels of
secretory IgA. This study demonstrates that transfer of
a microbiota from an IgA-low mice, by co-housing or
fecal transplantation, can lower fecal IgA levels in IgA-
high mice [17]. This study also shows that IgA-low
mice are more susceptible to challenges such as Dextran
Sulfate Sodium (DSS)-induced colitis, and that such sus-
ceptibility can be transferred to IgA-high mice by fecal
transplantation and are driven by fecal IgA differences via
a mechanism involving the ability of bacteria from IgA-
low mice to degrade sIgA [17]. Altogether, those findings
highlight the close relationship occurring between sIgA
repertoire and the microbiota, with a key role played in
the maintenance of intestinal homeostasis.
A common feature of colitis-associated microbiota are
increased levels of bioactive flagellin and lipopolysac-
charide (LPS), which can activate Toll-like receptor 5
(TLR5), NOD-like Receptor 4 (NLRC4) inflammasome,
and TLR4 [18–20]. Approaches to manipulate the
microbiota to make it inherently less pro-inflammatory
(i.e. reduce levels of innate immune activators) may
ultimately provide a novel approach to prevent and/or
treat Inflammatory Bowel Disease (IBD). Published ob-
servations demonstrating that the level of microbiota
flagellin expression inversely correlates with levels of
fecal anti-flagellin antibodies suggests that the adaptive
immune system possess the ability to alter the micro-
biota to make it less pro-inflammatory (Fig. 1) [21, 22].
Indeed, in a study published in Cell Host and Microbes
in 2013, it was demonstrated that TLR5-/- mice harbor a
reduced level of flagellin specific IgA [21]. Importantly,
the intestinal microbiota of those TLR5-/- animals was
found to express significantly higher amounts of bio-
active flagellin, supporting an impact of intestinal IgA in
suppressing levels of flagellin, likely by putting flagellated
bacteria at a competitive disadvantage within a complex
microbial community.
In addition, recent findings made by flow-cytometric
sorting suggest that IgA may mark commensal and
pathobionts according to the extent of their individual
coating [23]. This study by Palm and colleagues show
that IgA coating selectively marks known disease-driving
members of the mouse and human intestinal microbiota
that can impact disease susceptibility and/or severity
[23]. Transfer of fecal IgA-coated from cohorts of
Kwashiorkor undernourished children into germ free
mice triggers a diet-dependent enteropathy with intes-
tinal inflammation and dysfunction, but could be pre-
vented by administering two IgA-targeted bacterial
species from a healthy microbiota (Clostridium scindens,
Akkermansia muciniphila) [24]. A targeted elimination
or replacement of disease-driving members of the intes-
tinal microbiota could be a first step in the development
of personalized, microbiota reshaping therapies.
Conclusions
Based on this appealing work by Rescigno and colleagues,
we can hypothesis that selected manipulation of the im-
mune system has the potential to alter gut microbiota
composition to make it inherently less pro-inflammatory
(i.e. more diverse and with a reduced level of innate
immune activators), reducing susceptibility to and/or
severity of intestinal inflammation development. IgA
may be used as a target to shape the intestinal bacterial
community in order to maintain a beneficial relation-
ship between the host and the microbiota.
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